|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of goods sold | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Loss from operations | |||||
| Other income (expense) | |||||
| Interest income | |||||
| Interest expense | |||||
| Loss on equity issuance | |||||
| Extinguishment of tranche liability | |||||
| Change in fair value of SEPA, warrant and revenue base redemption liabilities | |||||
| Change in fair value of contingent earnout liability | |||||
| Other expense, net | |||||
| Loss before income taxes | |||||
| Income tax expense | |||||
| Net loss | |||||
| Series A Preferred Stock conversion inducement | |||||
| Deemed dividend related to Series B-2 preferred stock down round provision | |||||
| Undeclared dividends on Series A Preferred Stock | |||||
| Net loss attributable to common stockholders | |||||
| Total net loss attributable to common stockholders | |||||
| Net loss per share, basic (in dollars per share) | |||||
| Total net loss per share, basic (in dollars per share) | |||||
| Net loss per share, diluted (in dollars per share) | |||||
| Total net loss per share, diluted (in dollars per share) | |||||
| Weighted average common shares outstanding, diluted (in shares) | |||||
| Total weighted average common shares outstanding, diluted (in shares) | |||||
Loading...